Description: Kancera AB (Publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops HDAC for the treatment of nerve inflammation and pain; and ROR1 inhibitors for the treatment of solid tumors and blood cancers. Kancera AB (Publ) was founded in 2010 and is based in Solna, Sweden.
Home Page: www.kancera.com
Karolinska Institutet Science Park
Solna,
171 65
Sweden
Phone:
46 8 50 12 60 80
Officers
| Name | Title |
|---|---|
| Dr. Thomas Olin Ph.D. | CEO & Director |
| Mr. Hans Richter | Chief Financial Officer |
| Dr. Martin Norin | Chief Operating Officer |
| Mr. Peter Selin | Exec. VP of Corp. Devel. |
| Dr. Niclas Brynne | Head of Clinical Devel. |
| Dr. Torbjörn Lundström | Chief Medical Officer |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.4359 |
| Price-to-Sales TTM: | 168.1946 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 5 |